ImmunityBio Near Regulatory Approval for Bladder Cancer Immunotherapy
ImmunityBio (NASDAQ:IBRX) reported a significant revenue increase in Q1, driven by Anktiva adoption, but continues to face high operating expenses. The company is awaiting FDA approval of its sBLA for papillary bladder cancer and has secured a deal with Tokyo-172 BCG to address supply issues and support global expansion.
Tickers: $IBRX
Topics: biotech bladder cancer immunotherapy regulatory updates revenue growth